The impact of CYP3A5*3, a CYP3A5 nonexpresser genotype, on inhibitory effects of diltiazem on tacrolimus metabolism has not been assessed. In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C 0D7 , C max and AUC 0-12 h for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively). Subsequently, a prospective study was carried out, patients were randomized to algorithm-predicted dosing or standard dosing. For CYP3A5 expressers, an algorithm guided by CYP3A5 and diltiazem significantly reduced tacrolimus maintenance dosage (P ¼ 0.009) and improved the accuracy of tacrolimus initial dose, resulting in reduction in out-of-range C 0 after initial dose (P ¼ 0.002) and dose adjustments (P ¼ 0.004). However, for CYP3A5 nonexpressers, primary end points were not achieved, and tacrolimus-sparing effect of diltiazem was not remarkable. Our study results show that CYP3A5 genotype-guided tacrolimus-diltiazem combination is a promising therapy in renal transplant recipients in the early postoperative stage.
Introduction
Tacrolimus is a member of calcineurin inhibitor (CNI) family that is widely used as an alternative to cyclosporine A to prevent allograft rejection in solid organ transplantation. In clinical practice, close therapeutic drug monitoring is required to optimize efficacy and to decrease toxicity of tacrolimus due to its narrow therapeutic index and highly variable pharmacokinetics. 1 The exposure to tacrolimus, which is largely hepatically cleared, is correlated with the expression and activity of the hepatic and intestinal cytochrome (P450) enzymes (CYP) 3A4 and 3A5. 2 Tacrolimus is a potent but expensive immunosuppressant, long-term treatment with tacrolimus is costly for both individuals and health insurance systems all over the world. Thus, tacrolimus-sparing agents that could decrease its maintenance dosage are in high demand. Some clinical studies have testified that calcium channel blocker diltiazem, an inhibitor of CYP3A4 and CYP3A5, 3 can increase tacrolimus concentrations. 4, 5 In clinical practice, calcium channel blocker diltiazem has been used widely as a tacrolimus-sparing agent across the world. However, considerable interpatient variability in diltiazem's tacrolimussparing effect has been observed in our clinical practice. Therefore, diltiazem's tacrolimus-sparing effect should be shown in each patient but not merely assumed.
Some studies have reported that the extent of pharmacokinetic drug-drug interactions may be partially genetically determined. [6] [7] [8] [9] [10] [11] For example, CYP2C19 inhibitor fluvoxamine has been shown to increase the areas under the curve (AUCs) of the CYP2C19 substrates omeprazole and lansoprazole in CYP2C19 extensive metabolizers but not in poor metabolizers. 8, [12] [13] [14] Similarly, CYP2D6 inhibitors paroxetine and quinidine have been shown to significantly increase the AUCs of CYP2D6 substrates flecainide, desipramine and venlafaxine, in CYP2D6 extensive metabolizers but not in poor metabolizers. 9, 15, 16 Therefore, studies considering genetic factors leading to interpatient variability in diltiazem's tacrolimus-sparing effect are warranted.
A number of genetic variants have been identified within CYP3A4 gene, but we found in our previous study that the frequencies of these single nucleotide polymorphisms (SNPs) were relatively low in Chinese population (o2%), thus we speculated that these rare SNPs were unlikely to be the main cause of interpatient variability in diltiazem's tacrolimus-sparing effect. A polymorphism with high frequency within intron 3 (6986A4G, CYP3A5*3 allele) of the CYP3A5 gene, which causes splicing defect that results in the absence of functional CYP3A5 protein in homozygous carriers (CYP3A5*3/*3, CYP3A5 nonexpressers), was considered to be the primary determinant of the CYP3A5 protein expression. 17 Therefore, CYP3A5*3 genotype was considered exclusively in our study. We retrospectively compared the inhibitory effects of diltiazem on the metabolism of tacrolimus between CYP3A5 expressers and nonexpressers, and then validated the results obtained from retrospective study by a prospective randomized controlled study.
Materials and methods
This work was performed in accordance with the current Declaration of Helsinki Principles. All patients gave their written informed consent and the protocol was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-Sen University. The study consists of two parts: retrospective study (Part 1) and prospective study (Part 2). In this cohort, all patients received triple immunosuppressive regimen composing of tacrolimus (Prograft; Fujisawa Ireland Limited, Killorglin, Ireland), mycophenolate mofetil (Cellcept; Roche, Basel, Switzerland) 1.0-1.5 g per day and prednisolone (Guangdong Huanan Pharmacy Ltd., Dongguan, China) 30 mg per day. According to the routine in KTD-SYSU, the initial dose (0.05-0.075 mg kg À1 twice daily) of tacrolimus was started on the second day after transplantation and subsequently adjusted to achieve target predose concentration between 5 and 10 ng ml À1 . A total of 48 patients in the cohort were concomitantly administered with diltiazem (30 mg, t.i.d.; Neptunus Pharmaceutical Co., Ltd., Shenzhen, China) as tacrolimus-sparing agent for financial consideration.
Data collection. Trough concentrations (C 0 ) of tacrolimus on day 7 after transplantation were obtained from all subjects. Whole-blood concentration-time profiles were available in a subgroup of patients when they took tacrolimus alone (n ¼ 36) or coadministered with diltiazem (n ¼ 30) for 2 weeks, because they took part in a previous clinical study. Venous blood samples (2 ml) were obtained before drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 h after dosing. The quantification of tacrolimus in human whole blood was achieved by liquid chromatographytandem mass spectrometry as described previously. 18 Trough concentration, peak concentration (C max ) and time to peak concentration (T max ) were taken directly from the observed concentration-time profiles. The AUC from 0 to 12 h (AUC 0-12 h ) was calculated using the linear trapezoidal rule. Correlations between C 0 with the AUC 0-12 h were assessed. Body weight, tacrolimus doses and serum creatinine were recorded on day 7 after transplantation and on the pharmacokinetic test day.
DNA extraction and genotyping. Total genomic DNA was extracted from peripheral leukocytes according to the method described previously. 19 The CYP3A5*3 (6986 A4G) polymorphism was determined by using a previously reported polymerase chain reaction (PCR) restriction fragment length polymorphism method. 20 Correctness of genotyping was confirmed by DNA sequencing for two cases of each genotype.
Statistical
analysis. Groups were compared using nonparametric tests. For analysis of continuous pharmacologic variables, we used patient genotypes as categorical independent variables. Mann-Whitney U-test was used for comparisons between two groups. HardyWeinberg equilibrium test was performed using appropriate w 2 -test. w 2 -Test was also used for comparisons between discrete variables. Multiple linear regression analysis was performed to develop a tacrolimus dosing algorithm guided by CYP3A5 genotype and diltiazem. For CYP3A5, only two states were used: expressers (CYP3A5*1/*1 and *1/*3) and nonexpressers (CYP3A5*3/*3). Spearman's correlation was used to evaluate the correlation between C 0 and AUC 0-12 h .
Statistical analysis was performed using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). The results are expressed as mean ± s.d. A P-value less than 0.05 was considered as statistically significant.
Part 2: prospective study Study population. A total of 32 patients who were genotyped for CYP3A5*3 before the renal transplantation in KTD-SYSU between August 2008 and August 2009 were enrolled. Among them, 16 were CYP3A5 expressers and 16 were nonexpressers. They were randomly assigned to 'control' or 'study' group, each group has eight CYP3A5 expressers and eight nonexpressers. In control group, patients received standard initial dose of tacrolimus (0.050-0.075 mg kg À1 ) without coadministration of diltiazem. In study group, diltiazem was coadministered, and initial dose of tacrolimus was based on the algorithm that was developed from retrospective study (Part 1) as follows:
053, where C 0 was based on the therapeutic trough concentration level (5-10 ng ml À1 ). CYP3A5*3/*3 was coded as 1, CYP3A5*1/*1 or *1/*3 was coded as 0. Coadministration of diltiazem was coded as 1. Immunosuppressive regimens used in these two groups were the same as those in the retrospective study. The inclusion and exclusion criteria were the same as those in the retrospective study.
End points. The primary end points were the comparisons between the study and control groups of the C 0 after the initial dose, the percentage of out-of-range C 0 after initial dose, the number of dose adjustments made to achieve therapeutic range and the dose requirement to reach therapeutic range. The secondary end points were to compare acute rejection rate within 2 weeks after transplantation and serum creatinine on 14 days after transplantation between the two groups.
DNA extraction and genotyping. Extraction methods of genomic DNA and genotyping for the CYP3A5*3 were the same as those described in the retrospective study.
Statistical analysis. Please refer to the retrospective study.
Results
Part 1: retrospective study Patient characteristics. As per diltiazem was coadministeration on day 7 after renal transplantation, we divided 144 patients into DTZ( þ ) (n ¼ 48) and DTZ(À) (n ¼ 96) groups. Whole-blood concentration-time profiles were obtained in 36 patients in DTZ(À) group and 30 patients in DTZ( þ ) group. There were no significant differences in age and gender distribution, mycophenolate mofetil and prednisone doses, and serum creatinine between DTZ(À) and DTZ( þ ) groups (Table 1) .
Genotype frequencies. Table 2 shows frequencies of CYP3A5 genotype in the study population of each group. The frequency expected for genotype was evaluated on the basis of Hardy-Weinberg equilibrium proportions. None of the observed frequencies was significantly different from the expected frequencies (P40.05). There were no significant differences in genotype distribution between DTZ(À) and DTZ( þ ) groups.
Effects of CYP3A5*3 genotype on pharmacokinetics of tacrolimus. In both DTZ(À) and DTZ( þ ) groups, doseadjusted trough concentrations of tacrolimus on day 7 after transplantation (C 0D7 ) in CYP3A5 expressers were significantly lower than those in CYP3A5 nonexpressers (Po0.001 in DTZ(À) group and P ¼ 0.012 in DTZ( þ ) group) ( Table 3) . Similar results were found about dose-adjusted C max and AUC 0-12 h . In both groups, T max was similar between CYP3A5 expressers and nonexpressers (Table 4) .
Effect of CYP3A5*3 genotype on the extent of diltiazem-tacrolimus interaction. Significant differences were found in the extent of diltiazem-tacrolimus interaction between CYP3A5 genotype groups. In CYP3A5 expressers, mean doseadjusted C 0D7 , C max and AUC 0-12 h for tacrolimus in DTZ( þ ) group reached up to 48.7% (P ¼ 0.001), 31.7% (P ¼ 0.002) and 38.2% (P ¼ 0.001) higher than those in DTZ(À) group; whereas in CYP3A5 nonexpressers, mean dose-adjusted C 0D7 of tacrolimus was similar in both groups (P ¼ 0.201), and mean dose-adjusted C max and AUC 0-12 h in DTZ( þ ) group were only 17.2% (P ¼ 0.028) and 18.5% (P ¼ 0.014) higher than those in DTZ(À) group (Tables 3 and 4) .
Correlation between C 0 and AUC 0-12 h . Correlation between C 0 and AUC 0-12 h was assessed in both DTZ(À) and DTZ( þ ) groups, and the results were: (1) in DTZ(À) group, C 0 vs AUC 0-12 h (r ¼ 0.810, Po0.001); (2) in DTZ( þ ) group, C 0 vs AUC 0-12 h (r ¼ 0.861, Po0.001).
Part 2: prospective study Patient characteristics. As shown in Table 5 , there were no significant differences in age and gender distribution between control and study groups.
Primary end points. For CYP3A5 expressers, the mean C 0 of tacrolimus after initial dose in study group was significantly higher than that in control group (6.85 ± 1.47 vs 4.02±1.58 ng ml
À1
, P ¼ 0.012; Table 5 ). A significant difference in the percent of out-of-range C 0 of tacrolimus (subtherapeutic, that is, lower than 5 ng ml À1 ) after initial dose was observed between the study and control groups (P ¼ 0.002) ( Table 5 ). Significantly less dose adjustments were required for patients in the study group (P ¼ 0.004) ( Table 5) . Dose requirement to reach therapeutic range in study group was 19.7% lower than that in control group (P ¼ 0.009) ( Table 5 ).
In comparison, for CYP3A5 nonexpressers, no significant difference was observed in the mean C 0 of tacrolimus after initial dose between control and study groups (P ¼ 0.815). Though one patient in study group had supratherapeutic C 0 level (that is, higher than 10 ng ml À1 ) after initial dose, the percent of out-of-range C 0 after initial dose was not different between two groups (P ¼ 0.301). All patients in control group reached the therapeutic range of tacrolimus after initial dose so no dose adjustment was needed. In study group, except for one patient who had supratherapeutic C 0 level of tacrolimus after initial dose required one dose adjustment to reach therapeutic range, the average number of dose adjustments was not different between control and study groups (P ¼ 0.317). Dose requirement to reach therapeutic range in study group was a little lower than that in control group but no significant difference was observed (P ¼ 0.093).
Secondary end points. For CYP3A5 expressers, only one patient in control group experienced acute rejection episode within 2 weeks after transplantation, however, acute rejection rate was not different between control and study groups (P ¼ 0.302). None of CYP3A5 nonexpressers had acute rejection. For both CYP3A5 expressers and nonexpressers, no statistically significant difference was observed in serum creatinine on day 14 after transplantation between control and study groups.
Discussion
Our study clearly showed the clinical impact of CYP3A5*3 genotype on tacrolimus pharmacokinetics: dose-adjusted C 0D7 , C max and AUC 0-12 h were higher in CYP3A5 nonexpressers than those in CYP3A5 expressers irrespective of Abbreviations: C 0D7 , trough concentration of tacrolimus on day 7 after transplantation; DTZ, diltiazem; CYP3A5, cytochrome P450 3A5. Data are mean values ± s.d.
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J-L Li et al diltiazem coadministration. This is in line with several previous studies. [21] [22] [23] [24] [25] Yet the most impressive finding is the influence of this SNP on the metabolic interaction between diltiazem and tacrolimus. When coadministered with diltiazem, the mean increments in dose-adjusted C 0D7 , C max and AUC 0-12 h for tacrolimus in CYP3A5 expressers were larger than those in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%), suggesting that CYP3A5 expressers are more susceptible to diltiazem-induced inhibition of tacrolimus metabolism.
Subsequent prospective randomized controlled study confirmed the finding of the retrospective study. For CYP3A5 expressers, those in study group required 19.7% less tacrolimus to achieve therapeutic range than those in control group. On the basis of the mean dose-adjusted C 0D7 and AUC 0-12 h from retrospective study, which suggested that diltiazem could increase them by 48.7 and 38.2%, respectively, we speculated that to achieve the same C 0 and AUC 0-12 h levels, patients coadministered with diltiazem should require 27.6-32.8% less tacrolimus. The 19.7% decline was a little lower than our expectation. But for CYP3A5 nonexpressers, both the C 0 after initial dose and dose needed to achieve therapeutic range did not differ significantly between the control and study groups, suggesting that tacrolimus-sparing effect of diltiazem on CYP3A5 nonexpressers was not remarkable.
Meanwhile, we found that algorithm-predicted tacrolimus dosing guided by CYP3A5 genotype and diltiazem, which was determined from retrospective study, significantly enhanced accuracy of tacrolimus initial dose in CYP3A5 expressers. Significant reduction in out-of-range C 0 after initial dose and dose adjustments suggests that CYP3A5 expressers in study group could achieve therapeutic trough concentration more rapidly than those in control group, which is of critical importance during initial period after transplantation that is characterized by the highest risk of organ rejection. To the best of our knowledge, this is the first dose-prediction algorithm guided by both pharmacogenetic and combination therapies for tacrolimus.
Furthermore, acute rejection rate and serum creatinine levels were not different between the study and control groups, indicating that coadministration of diltiazem did not affect the immunosuppressive effect of tacrolimus or allograft function in study period. Besides, previous studies showed that diltiazem brings about not only functional, but also morphological improvement in tacrolimus-induced acute nephrotoxicity, and is effective in the prevention of ischemic damage, 26, 27 suggesting that diltiazem is an appropriate tacrolimus-sparing agent.
Diltiazem is a potent mechanism-based inhibitor of CYP3A. 3 It contains an amino functional group and undergoes N-demethylation through CYP3A, its metabolites bind tightly and irreversibly to CYP3A to form the metabolic intermediate complex (MIC) that results in inactivation of CYP3A. 28 Yamaori et al. 29 found that the CYP3A5 contents correlated well with liver microsomal activities of diltiazem N-demethylation among subjects carrying at least one CYP3A5*1 allele compared with CYP3A4, and the correlation coefficient of CYP3A5 contents with the rates of diltiazem N-demethylation was higher than those of CYP3A4. So the authors suggested that polymorphic expression of CYP3A5 may partly account for the variation in the metabolism of CYP3A substrates.
29 CYP3A5*1 carrier state is associated with higher hepatic and intestinal CYP3A5 expression and activity, [30] [31] [32] [33] thus in CYP3A5 expressers, more diltiazme N-demethylation metabolites are formed resulting in stronger inhibition of CYP3A activity, which might explain the finding of our study. In addition, in recent years, expression of CYP3A enzyme has been shown to be transcriptionally regulated by nuclear receptor pregnane X receptor (PXR). 34 Several SNPs in PXR have been found to be associated with CYP3A4 expression. 35, 36 Studies evaluating the influences of PXR genotype on CYP3A5 expression and diltiazem's tacrolimus-sparing effect are warranted.
C 0 levels are used in clinical settings for therapeutic drug monitoring of tacrolimus for its good correlation with the AUC. 1, 37 Our study investigated whether such a good correlation would be affected by coadministration of diltiazem, which was not studied before. The results showed similar correlation between DTZ( þ ) and DTZ(À) groups (r ¼ 0.861 vs 0.810), suggesting that C 0 is still a good index of drug exposure of tacrolimus when diltiazem is coadministered.
In conclusion, renal transplant recipients with CYP3A5*1 allele (CYP3A5 expressers) are more susceptible to diltiazeminduced inhibition of tacrolimus metabolism in comparison to CYP3A5*3/*3 carriers (CYP3A5 nonexpressers). Algorithm-predicted tacrolimus dosing guided by CYP3A5 genotype and diltiazem is more closely predictive of tacrolimus initial dose for CYP3A5 expressers. CYP3A5 genotype-guided tacrolimus-diltiazem combination is a promising therapy in renal transplant recipients in the early postoperative stage.
